Skip to main content

Advertisement

SpringerLink
Log in

Applications of Cardiac Computed Tomography in the Cardio-Oncology Population

  • Cardio-oncology (MG Fradley, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The increased risk for cardiovascular events in aging cancer survivors and those undergoing certain chemotherapeutic treatments has raised concern for more rigorous screening and surveillance methods above that of the general population. At this time, there are limited guidelines for how to best manage this vulnerable cohort. Questions regarding timing of screening, choice of imaging modality and risk reduction strategies—especially in those patients with known atherosclerotic disease—remain to be elucidated. Over a decade of case series, retrospective studies and clinical trials have shed light on the evolving role of cardiac computed tomography (CT) in this population, of which there is a relative paucity of data regarding its potential utility in the specific cardio-oncology population. Focusing on ability of cardiac CT to evaluate multiple cardiac and vascular structures, provide diagnostic and prognostic information, as well as assist interventional and surgical colleagues in surgical/percutaneous valve replacement and revascularization strategies is the premise for this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Explore related subjects

Discover the latest articles, news and stories from top researchers in related subjects.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.

    Article  Google Scholar 

  2. Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “silver tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers. 2016;25(7):1029–36.

    Article  Google Scholar 

  3. Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi JJ. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J. 2014;35(10):612–23.

    Article  Google Scholar 

  4. Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457–67.

    Article  CAS  Google Scholar 

  5. Potts JE, Kwok CS, Rashid M, Mamas MA, Iliescu CA, Lopez Mattei JC, et al. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. 2018

  6. Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31(29):3673–80.

    Article  Google Scholar 

  7. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13(3):R64.

    Article  Google Scholar 

  8. Dehal AN, Newton CC, Jacobs EJ, Patel AV, Gapstur SMCP. Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2012;1(30):53–9.

    Article  Google Scholar 

  9. Abdel-Qadir H, Austin PCLD. A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol. 2017;2(1):88–93.

    Article  Google Scholar 

  10. Whitlock MC, Yeboah J, Burke GL, Chen H, Klepin HD, Hundley WG. Cancer and its association with the development of coronary artery calcification: an assessment from the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2015;4(11):e002533.

    Article  Google Scholar 

  11. Hershman DL, Till C, Shen S, Wright JD, Ramsey SD, Barlow WE, et al. Association of cardiovascular risk factors with cardiac events and survival outcomes among patients with breast cancer enrolled in SWOG clinical trials. J Clin Oncol. 2018;36(26):2710–7.

    Article  Google Scholar 

  12. Singh J, Valero-Elizondo J, Salami JA, Warraich HJ, Ogunmoroti O, Spatz ES, et al. Favorable modifiable cardiovascular risk profile is associated with lower healthcare costs among cancer patients: the 2012-2013 medical expenditure panel survey. J Am Heart Assoc. 2018;7(9):e007874.

    Article  Google Scholar 

  13. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al. Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. Circulation. 2016;133(13):1272–89.

    Article  CAS  Google Scholar 

  14. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25(25):3991–4008.

    Article  CAS  Google Scholar 

  15. Russell RR, Alexander J, Jain D, Poornima IG, Srivastava AV, Storozynsky E, et al. The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. J Nucl Cardiol. 2016;23:856–84.

    Article  Google Scholar 

  16. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35:893–911.

    Article  Google Scholar 

  17. Labianca R, Beretta G, Clerici M, Fraschini PLG. Cardiac toxicity of 5-FU: a study of 1,083 patients. Tumori. 1982;68:505–10.

    Article  CAS  Google Scholar 

  18. Layoun ME, Wickramasinghe CD, Peralta MV, Yang EH. Fluoropyrimidine-induced cardiotoxicity: manifestations, mechanisms, and management. Curr Oncol Rep. 2016;18:35.

    Article  Google Scholar 

  19. Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P. Cardiac risk after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol. 1998;46(1):51–62.

    Article  CAS  Google Scholar 

  20. de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD. Management of antiangiogenic therapy-induced hypertension. Hypertension. 2012;60(3):607–15.

    Article  Google Scholar 

  21. Virani SA, Brezden-Masley C, Clarke B, Davis MK, Jassal DS, Johnson C, et al. Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol. 2016;32:831–41.

    Article  Google Scholar 

  22. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911–39.

    Article  Google Scholar 

  23. Kim KP, Einstein AJ, Berrington de González A. Coronary artery calcification screening: estimated radiation dose and cancer risk. Arch Intern Med. 2009;169(13):1188–94.

    Article  Google Scholar 

  24. Rozanski A, Gransar H, Shaw LJ, Kim J, Miranda-Peats L, Wong ND, et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing: the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J Am Coll Cardiol. 2011;57(15):1622–32.

    Article  CAS  Google Scholar 

  25. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol 2018;25709.

  26. Roos CTG, van den Bogaard VAB, Greuter MJW, Vliegenthart R, Schuit E, Langendijk JA, et al. Is the coronary artery calcium score associated with acute coronary events in breast cancer patients treated with radiotherapy? Radiother Oncol. 2018;126(1):170–6. Elevated coronary artery calcium scores are associated with higher cardiovascular event rates in breast cancer patients.

    Article  CAS  Google Scholar 

  27. • Hughes-Austin JM, Dominguez A 3rd, Allison MA, Wassel CL, Rifkin DE, Morgan CG, et al. Relationship of Coronary Calcium on Standard Chest CT Scans With Mortality. JACC Cardiovasc Imaging. 2016;9(2):152–9. Oncologists can use non-ECG gated chest CT coronary artery calcium scores to assist in cardiovascular risk stratification.

    Article  Google Scholar 

  28. Hecht HS, Blaha MJ, Kazerooni EA, Cury RC, Budoff M, Leipsic J, et al. CAC-DRS: coronary artery calcium data and reporting system. An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). J Cardiovasc Comput Tomogr. 2018;12(3):185–91.

    Article  Google Scholar 

  29. Garg PK, Jorgensen NW, McClelland RL, Leigh JA, Greenland P, Blaha MJ, et al. Use of coronary artery calcium testing to improve coronary heart disease risk assessment in a lung cancer screening population: the Multi-Ethnic Study of Atherosclerosis (MESA). J Cardiovasc Comput Tomogr. 2018;12(6):493–9.

    Article  Google Scholar 

  30. Lu MT, Onuma OK, Massaro JM, D’Agostino RB, O’Donnell CJ, Hoffmann U. Lung cancer screening eligibility in the community: cardiovascular risk factors, coronary artery calcification, and cardiovascular events. Circulation. 2016;134(12):897–9.

    Article  Google Scholar 

  31. Andersen R, Wethal T, Günther A, Fosså A, Edvardsen T, Fosså SD, et al. Relation of coronary artery calcium score to premature coronary artery disease in survivors >15 years of Hodgkin’s lymphoma. Am J Cardiol. 2010;105(2):149–52.

    Article  Google Scholar 

  32. Lancellotti P, Edvardsen T, Gaemperli O, Galderisi M, Griffin B, Plana JC, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14(8):721–40.

    Article  Google Scholar 

  33. Amsterdam EA, et al. AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes. Circulation. 2014;130(25):e344–426.

    PubMed  Google Scholar 

  34. Chinnaiyan KM, Raff GL, Goraya T, Ananthasubramaniam K, Gallagher MJ, Abidov A, et al. Coronary computed tomography angiography after stress testing: results from a multicenter, statewide registry, ACIC (Advanced Cardiovascular Imaging Consortium). J Am Coll Cardiol. 2012;59(7):688–95.

  35. Litt HI, Gatsonis C, Snyder B, Singh H, Miller CD, Entrikin DW, et al. CT angiography for safe discharge of patients with possible acute coronary syndromes. N Engl J Med. 2012;366(15):1393–403.

    Article  CAS  Google Scholar 

  36. Investigators S-H, Newby DE, Adamson PD, Berry C, Boon NA, Dweck MR, et al. Coronary CT angiography and 5-year risk of myocardial infarction. N Engl J Med. 2018;379:924–33. The SCOT-HEART investigators provided insight into the mortality benefit of CCTA in a stable chest pain population.

  37. Douglas PS, Pontone G, Hlatky MA, Patel MR, Norgaard BL, Byrne RA, et al. Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFRct: outcome and resource impacts stud. Eur Heart J. 2015;36(47):3359–67.

    Article  CAS  Google Scholar 

  38. Redheuil AB, Azarine A, Garrigoux P, Mousseaux E. Correspondence between delayed enhancement patterns in multislice computed tomography and magnetic resonance imaging in a case of acute myocarditis. Circulation. 2006;114(19):e571–2.

    Article  Google Scholar 

  39. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98.

    Article  CAS  Google Scholar 

  40. van Nimwegen FA, Schaapveld M, Janus CPM, Krol ADG, Petersen EJ, Raemaekers JMM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007–17. Van Nimwegen et al. provided extensive longitudinal efforts in defining long-term cardiovascular risk in a Hodgkin lymphoma population.

    Article  Google Scholar 

  41. van Leeuwen-Segarceanu EM, Bos WJW, Dorresteijn LDA, Rensing BJWM, van d HJAS, Vogels OJM, et al. Screening Hodgkin lymphoma survivors for radiotherapy induced cardiovascular disease. Cancer Treat Rev. 2011;37(5):391–403.

    Article  Google Scholar 

  42. Chinnasami BR, Schwartz RC, Pink SB, Skotnicki RA. Isolated left main coronary stenosis and mediastinal irradiation. Clin Cardiol. 1992;15:459–61.

    Article  CAS  Google Scholar 

  43. •• Chao C, Xu L, Bhatia S, Cooper R, Brar S, Wong FL, et al. Cardiovascular disease risk profiles in survivors of adolescent and young adult (AYA) cancer: the Kaiser Permanente AYA Cancer Survivors study. J Clin Oncol. 2016;34(14):1626–33 Chao et al. confirmed the increased risk of cardiovascular disease in cancer population compared to the general public, especially in those with prior leukemia or breast cancer.

    Article  CAS  Google Scholar 

  44. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831–7.

    Article  CAS  Google Scholar 

  45. Heidenreich PA, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol. 2007;25(1):43–9.

    Article  Google Scholar 

  46. Rademaker J, Schroder H, Ariaratnam NS, Strauss HW, Yahalom J, Steingart R, et al. Coronary artery disease after radiation therapy for Hodgkin’s lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients. Am J Roentgenol. 2008;191(1):32–7.

    Article  Google Scholar 

  47. Küpeli S, Hazirolan T, Varan A, Akata D, Alehan D, Hayran M, et al. Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin’s lymphoma. J Clin Oncol. 2010;28(6):1025–30.

    Article  Google Scholar 

  48. The National Comprehensive Cancer. NCCN guidelines version 3.2018. Hodgkin lymphoma. Version 3.2018, 08/31/18 © National Comprehensive Cancer Network, Inc. 2018, All rights reserved.

  49. Dijos M, Reynaud A, Leroux L, Réant P, Cornolle C, Roudaut R, et al. Efficacy and follow-up of transcatheter aortic valve implantation in patients with radiation-induced aortic stenosis. Open Hear. 2015;2(1):e000252.

    Article  Google Scholar 

  50. Bouvier E, Logeart D, Sablayrolles JL, Feignoux J, Scheublé C, Touche T, et al. Diagnosis of aortic valvular stenosis by multislice cardiac computed tomography. Eur Heart J. 2006;27:3033–8.

    Article  Google Scholar 

  51. Buttan AK, Yang EH, Budoff MJ, Vorobiof G. Evaluation of valvular disease by cardiac computed tomography assessment. J Cardiovasc Comput Tomogr. 2012;6(6):381–92.

    Article  Google Scholar 

  52. Blanke P, Weir-McCall JR, Achenbach S, Delgado V, Hausleiter J, Jilaihawi H, et al. Computed tomography imaging in the context of transcatheter aortic valve implantation (TAVI)/transcatheter aortic valve replacement (TAVR): an expert consensus document of the Society of Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr. 2019;13:1–20.

    Article  Google Scholar 

  53. Schechter M, Balanescu DV, Donisan T, Dayah TJ, Kar B, Gregoric I, et al. An update on the management and outcomes of cancer patients with severe aortic stenosis. Catheter Cardiovasc Interv 2018;1–8.

  54. Landes U, Iakobishvili Z, Vronsky D, Zusman O, Barsheshet A, Jaffe R, et al. Transcatheter aortic valve replacement in oncology patients with severe aortic stenosis. JACC Cardiovasc Interv. 2019;12(1):78–86.

    PubMed  Google Scholar 

  55. Pollak AW, Norton P, Kramer CM. Multimodality imaging of lower extremity peripheral arterial disease: current role and future directions. Circ Cardiovasc Imaging. 2012;5(6):797–807.

    Article  Google Scholar 

  56. El Tahlawi M, Jop B, Bonello B, Dragulescu A, Rouault F, Habib G, et al. Should we close hypoxaemic patent foramen ovale and interatrial shunts on a systematic basis. Arch Cardiovasc Dis. 2009;102(11):755–9.

    Article  Google Scholar 

  57. Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013;27:1316–21.

    Article  CAS  Google Scholar 

  58. Aichberger KJ, Herndlhofer S, Schernthaner G-H, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533–9.

    Article  CAS  Google Scholar 

  59. Cortes JE, Kim D, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–96.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Knight Cardiovascular Institute, Division of Cardiology, Department of Medicine, Oregon Health & Science University, 3180 Sam Jackson Park Rd., Mail Code UHN62, Portland, OR, 97239, USA

    Michael E. Layoun MD & Maros Ferencik MD, PhD, MCR

  2. UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA

    Eric H. Yang MD

  3. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA

    Joerg Herrmann MD

  4. Department of Cardiology, Division of Internal Medicine, M.D. Anderson Cancer Center, Houston, TX, USA

    Cezar A. Iliescu MD & Juan C. Lopez-Mattei MD

  5. Premier Heart and Vascular Group, Florida Hospital Pepin Heart Institute, Tampa, FL, USA

    Kostas Marmagkiolis MD

  6. Division of Cardiology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA

    Matthew J. Budoff MD

Authors
  1. Michael E. Layoun MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric H. Yang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joerg Herrmann MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cezar A. Iliescu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juan C. Lopez-Mattei MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kostas Marmagkiolis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Matthew J. Budoff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maros Ferencik MD, PhD, MCR
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maros Ferencik MD, PhD, MCR.

Ethics declarations

Conflict of Interest

Michael E. Layoun declares that he has no conflict of interest.

Eric H. Yang declares that he has no conflict of interest.

Joerg Herrmann declares that he has no conflict of interest.

Cezar A. Iliescu declares that he has no conflict of interest.

Juan C. Lopez-Mattei declares that he has no conflict of interest.

Kostas Marmagkiolis declares that he has no conflict of interest.

Matthew J. Budoff has received research funding from General Electric.

Maros Ferencik has received research funding from the American Heart Association and the National Institutes of Health.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Topical Collection on Cardio-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Layoun, M.E., Yang, E.H., Herrmann, J. et al. Applications of Cardiac Computed Tomography in the Cardio-Oncology Population. Curr. Treat. Options in Oncol. 20, 47 (2019). https://doi.org/10.1007/s11864-019-0645-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-019-0645-2

Keywords

Search

Navigation